Cisplatin is a chemotherapeutic drug commonly used in clinics. However, acquired resistance confines its application in chemotherapeutics. To overcome the acquired resistance to cisplatin, it is reasoned, based on our previous findings of mediation of cellular responses by [Gd@C 82 (OH) 22 ] n nanoparticles, that [Gd@C 82 (OH) 22 ] n may reverse tumor resistance to cisplatin by reactivating the impaired endocytosis of cisplatin-resistant human prostate cancer (CP-r) cells. Here we report that exposure of the CP-r PC-3-luc cells to cisplatin in the presence of nontoxic [Gd@C 82 (OH) 22 ] n not only decreased the number of surviving CP-r cells but also inhibited growth of the CP-r tumors in athymic nude mice as measured by both optical and MRI. Labeling the CP-r PC-3 cells with transferrin, an endocytotic marker, demonstrated that pretreatment of the CPr PC-3-luc cells with [Gd@C 82 (OH) 22 ] n enhanced intracellular accumulation of cisplatin and formation of cisplatin-DNA adducts by restoring the defective endocytosis of the CP-r cancer cells. The results suggest that [Gd@C 82 (OH) 22 ] n nanoparticles overcome tumor resistance to cisplatin by increasing its intracellular accumulation through the mechanism of restoring defective endocytosis. The technology can be extended to other challenges related to multidrug resistance often found in cancer treatments.
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drug resistance | nanomedicine | nanoimaging | chemotherapy | nanopharmaceutical A s a major chemotherapeutic agent for tumor treatment, cisplatin remains a cornerstone of the present-day chemotherapy regimens against not only epithelial malignancies but also a number of metastatic and advanced malignancies (1, 2) . However, because of high toxicity and easy development of drug resistance, successful treatment with cisplatin often is limited (3, 4) . Following the discovery of ATP-binding cassette (ABC) transporters and their roles in drug resistance in various types of tumors (5) , much research has been done to explore the relationship between ABC transporter activity and specific chemotherapeutics, including cisplatin. Because no ABC transporter has been identified for "pumping" cisplatin out of cisplatin-resistant human prostate cancer (CP-r) cells (6) (7) (8) , it would be difficult to sensitize CP-r cells by using any known strategy that targets resistant cancer cells by inhibiting multidrug resistance (MDR)-associated proteins on plasma membrane of the CP-r cells. Diffusion has been considered as a pathway for cisplatin to penetrate plasma membrane. Recently, studies have indicated that cisplatin entered cells by endocytosis and other mechanisms (9) (10) (11) (12) .
To increase susceptibility of cancer cells to cisplatin, i.e., to reverse drug resistance, many efforts have been made through chemical modification, gene therapy, vector delivery, and other means (2, 9, 13) . Combination of traditional chemotherapy with nanotechnology may provide a promising alternative for novel cancer treatments. The use of nanoparticles to sensitize tumor cells to cisplatin in vitro and in vivo has been described recently (14) (15) (16) . In these studies, cisplatin-encapsulated nanoparticles were used to control release of cisplatin into the CP-r cells (15) , and the effects were cell-line specific (16) . Nanoparticles have potential for a wide range of biomedical and biotechnological applications. Fullerene molecules, the third form of pure carbon in addition to the diamond and graphite forms, have attracted much attention to their biomedical applications (17) . It has been demonstrated that fullerenes can generate singlet oxygen and suppress tumor growth without damage to normal skin of the mice exposed to visible light (18) . We have found that metallofullerene nanoparticles penetrate plasma membrane of tumor cells and result, to some degree, in shrinkage of solid tumors in vivo (19, 20) . As a proof of concept, we have demonstrated that the metallofullerene nanoparticles, formulated as [Gd@C 82 (OH) 22 ] n , are able to effectively inhibit proliferation of solid tumors and to decrease the activities of those enzymes responsible for catalyzing the production of reactive oxygen species in vivo (20) (21) (22) . In addition, [Gd@C 82 (OH) 22 ] n nanoparticles did not show significant side effects in vivo. In the present study, we showed that multihydroxylated metallofullerene nanoparticles ([Gd@C 82 -(OH) 22 ] n ) could reactivate the defective endocytosis of cisplatin in the CP-r cells and cause accumulation of intracellular cisplatin in the CP-r cells. Consequently, tumor resistance to cisplatin was circumvented by treatment with a combination of [Gd@C 82 -(OH) 22 ] n with cisplatin both in vitro and in vivo.
Results and Discussion
Physical Properties and Characterization of [Gd@C 82 (OH) 22 ] n nanoparticles. Metallofullerenes with gadolinium (Gd) have been demonstrated to be capable of effectively enhancing magnetic resonance image contrast (23) . [Gd@C 82 (OH) 22 ] n , synthesized by our group, has been verified as a new generation of highly efficient contrast agents for magnetic resonance imaging (MRI) (24) (25) (26) (27) . It is a hydroxylated fullerene forming a cage encapsulating gadolinium inside (Fig. S1 ). The multihydroxylated amphiphilic metallofullerene [Gd@C 82 (OH) 22 ] n self-assembles in aqueous solution to form nanoparticles. These nanoparticles do not exist as individual molecules or molecular ions but as aggregates. The average size of [Gd@C 82 (OH) 22 ] n aggregates is 50 ± 12 nm, measured by dynamic light scattering (DSL). The particles form nonuniform quasi-spherical shapes. The [Gd@C 82 (OH) 22 ] n nanoparticles self-assemble into a hexagonal microstructures that are visible by scanning electron microscopy ( Fig. 1 A and B) . This multihydroxylated metallofullerene does not show significant in vivo toxicity as evidenced by morphological analysis of HE staining various tissues of tumor-bearing animals (Fig. 1C) . Protonation or deprotonation of [Gd@C 82 (OH) 22 ] n varies the negative charges of the hydroxyl groups, which further modulates the repulsive static electric forces among the [Gd@C 82 (OH) 22 ] n species (28) . These repulsive static-electric forces could affect the size of hydrophobic-forceinduced self-assembly of [Gd@C 82 (OH) 22 ] n nanoparticles. The size determines the nanoparticle-mediated cellular response, and particle size at 40-60 nm appears to have the greatest effects (29).
Development of PC-3 luc Cells Resistant to Cisplatin. In this study, we proposed that [Gd@C 82 (OH) 22 ] n nanoparticles reverse tumor resistance by enhancing the endocytosis of cisplatin via nanoparticle-mediated penetration through the plasma membrane of the CP-r cells. To test this hypothesis in vivo and in vitro, human prostate cancer PC-3-luc cells were chosen to establish cisplatinresistant (CP-r) cells. Luciferase expressed in PC-3 cells was used as a marker to facilitate optical imaging of the CP-r cells. We found that the CP-r PC-3-luc colonies appeared at a frequency of ≈1/10 6 in the presence of cisplatin. The CP-r variants were identified, isolated, and cloned after the parental cisplatin-sensitive (CP-s) cells were exposed to 1 μg/mL cisplatin for 2 months (Fig. S2) . To measure cytotoxicity, we cultured the resistant cells in cisplatinfree medium for 10 days before conducting the cisplatin cytotoxicity assay. The resistant index (RI) of the CP-r cells was found to be 6-fold higher than that of the parental CP-s cells ( Fig. 2A) .
[Gd@C 82 (OH) 22 ] n Sensitized CP-r Cells to Cisplatin Treatment in Vitro and in Vivo. The CP-r cells were treated with various concentrations of [Gd@C 82 (OH) 22 ] n nanoparticles (1-50 μM) with or without 1 μg/mL cisplatin (Fig. 2B) . The IC 50 value of cisplatin against parental CP-s cells was 1 μg/mL, the concentration that was used for inducing the CP-r variants and was virtually nontoxic to the CP-r cells. Treatment with [Gd@C 82 (OH) 22 ] n nanoparticles alone had no significant effect on either CP-s or CP-r cells at concentrations lower than 10 μM (Fig. S2) . Treatment with nanoparticles alone did not change proliferation of the CP-r PC-3-luc cells, nor did cisplatin at 1 μg/mL dosage. However, the number of surviving CP-r cells decreased by ∼30% after a combined treatment of 1 μg/mL cisplatin and [Gd@C 82 (OH) 22 ] n nanoparticles compared with the nanoparticle or cisplatin treatment alone (Fig. 2B) . To further confirm the ability of nanoparticles to overcome cisplatin resistance in vivo, we developed a solid tumor mouse model by s. 22 ] n nanoparticles improved the inhibition of CP-r tumors growth by cisplatin. As luciferase is expressed in both the CP-s and CP-r PC-3-luc cells, these prostate cancer cells growing as s.c. tumors on the flanks of the mice can be readily optically imaged in vivo. Representative images of the mice following the 4-week treatment protocol confirmed similarities in CP-s and CP-r tumor proliferation between groups treated with saline or NP. Cisplatin alone was highly efficient at inhibiting CP-s PC-3-luc tumors in vivo but had virtually no effect on the growth of CP-r PC-3-luc tumors in vivo. In contrast, cisplatin combined with the nanoparticles (cisplatin+NP group) inhibited growth of both the cisplatin-sensitive PC-3-luc tumors (as expected) and the cisplatinresistant PC-3-luc tumors. The sizes of the CP-s PC-3-luc and CPr PC-3-luc tumors after the combined treatment were very similar ( Fig. 2C and Fig. 3A) . MRI images also showed reduced sizes of were plated in 96-well plates with 100 μL medium per well. After 6 h, various concentrations of cisplatin in 50 μL medium were added, and the cells were incubated at 37°C for 3 days. Before the cell viability measurement, 10 μL of MTT solution (Kumamoto) was added to each well and incubated for 2 h. Cell viability was measured using spectrophotometry. (B) Measurement of [Gd@C 82 (OH) 22 ] n nanoparticle cytotoxicity in CP-r cells treated or untreated with cisplatin (1 μg/mL). The protocol was the same as described in Fig. 2A . Results shown are the average of three different experiments. (C) Tumor weight was measured by caliper quantification {tumor weight (mg) = tumor density (1 mg/mm 3 ) × length (mm) × [width (mm) 2 / 2]} (i, CP-s PC-3-luc; ii, CP-r PC-3-luc). Nanoparticles (20 μM) were used. Tumor volumes were derived from consecutive multiple MRI images using Image J software (iii, CP-s PC-3-luc; iv, CP-r PC-3-luc). Statistical analysis of Inset C using ANOVA shows a significant difference between two sets of data when P < 0.05. CP-r and CP-s tumors following the cisplatin plus nanoparticle treatment. A series of multislice MRI images were used to study tumor morphology (shape and location) (Fig. 3B) . The tumor volume was calculated based on these consecutive MRI images, after which the tumor weight was also statistically calculated and deduced (Fig. 3C) . The effect of the nanoparticles on cisplatin treatment was clearly demonstrated in Fig. 3 A and B and as shown by the images of the individual groups (Fig. S3) . These studies confirmed that [Gd@C 82 (OH) 22 ] n nanoparticles increased the sensitivity of CP-r PC-3-luc tumors to cisplatin in vivo.
Intracellular Cisplatin Accumulation by Reactivating the Defective
Endocytosis in CP-r Cells. Nanoparticles have been used to deliver drugs or genes for cancer treatment using the unique characteristics associated with the nanoscale size (30, 31) . It is known that tumors become resistant to cisplatin, partially because of reduced uptake of cisplatin resulting from an endocytic defect following defective formation of the endocytic recycling compartment (ERC) (32) . Although the specific molecular or regulatory defect responsible for the reduced accumulation of cisplatin in the CP-r cells has not been identified, several proteins have been found to be associated with this phenotype (33, 34) . To investigate how metallofullerene [Gd@C 82 (OH) 22 ] n nanoparticles increase cisplatin toxicity in the CP-r cancer cells, the CP-s and CP-r PC-3-luc cells were labeled with Texas Redtransferrin, a bona fide marker of the endocytic recycling pathway. In the parental CP-s PC-3-luc cells, we observed that transferrin localized close to the nucleus as a bright patch of fluorescence. Unlike the pattern observed in the CP-s cells, transferrin was distributed more peripherally in the CP-r cells as discrete punctate structures. In general, there was less intracellular transferrin in CP-r cells compared with CP-s cells ( 4). The difference in transferrin distribution between the CP-r and CP-s cells may result from defective endocytosis of the CP-r cells as demonstrated by our previous studies (32, 35) . Cisplatin passes through the plasma membrane and enters cells in part by endocytosis (36) (37) (38) . We believe that multihydroxylated metallofullerene [Gd@C 82 (OH) 22 ] n nanoparticles reactivate endocytosis through their unique nanoscale properties. The reasoning was confirmed by increased nanoparticle-mediated endocytosis in CP-r cells compared with CP-r cells treated with cisplatin alone (Fig. 4 A-E and G). This was also confirmed by increased cisplatin adducts in NP+CP-treated CP-r cells measured using inductively coupled plasma mass spectroscopy (ICP-MS) in the negative ion mode (Fig. 4F) . Inhibition of endocytosis by cytochalasin D of Bafilomysin A1 decreased the nanoparticle-activated cisplatin intracellular accumulation (Figs. S4 and S5 ). This suggests that [Gd@C 82 (OH) 22 ] n nanoparticles restore endocytotic function and increase intracellular cisplatin accumulation in CP-r PC-3-luc variants.
Summary. Cisplatin is commonly used to treat prostate cancer at early clinical stages. However, the ability of prostate cancer cells to become resistant to cisplatin remains a significant impediment to successful chemotherapy of prostate cancer patients. It is known that cisplatin enters cells by different pathways such as passive diffusion (39, 40) , transportation (41, 42) , and endocytosis (14) (15) (16) , which may be cell-line dependent. Until now, the generally accepted mechanisms by which cells become resistant to cisplatin have been (i) enhanced repair ability and tolerance of nuclear lesions leading to apoptosis; (ii) increased detoxification of cisplatin by metallothionein and glutathione; and (iii) diminished accumulation of cisplatin (2, 6, 8) . Of these mechanisms, accumulation defect seems to be dominant in various cell lines (8, 43) . As mentioned above, CP-r cells have a defect in endocytosis (32) , which may lead to diminished accumulation of cisplatin and confer the cells on resistance against extracellular cisplatin. The restored endocytosis of transferrin by [Gd@C 82 (OH) 22 ] n nanoparticles indicated that the nanoparticles can circumvent the acquired resistance of the CP-r PC-3-luc variants by enhancing uptake of cisplatin ( Fig. 5 and Movie S1). Cisplatin sensitivity was also increased by nanoparticles in CP-r KB-3-1 and BEL 7404 cells (Fig. S6) . Because intracellular accumulation of cisplatin is reduced in CP-r cells due to a pleiotropic defect, other mechanisms such as reduced fluidity of plasma membrane or altered cytoskeleton may also contribute to the [Gd@C 82 (OH) 22 ] n nanoparticle reversal of the cisplatin resistance in vitro and in vivo (9, 10) . Bioeffect of nanoparticles was measured with LIVE/DEAD Viability/Cytotoxicity by using confocal microscopy (Fig. S7 ). These nanoparticles are surprisingly nontoxic to cancer cells in vitro, yet can successfully enhance the growth inhibition by cisplatin on CP-r tumor in vivo. The in vivo enhancing effect of the nanoparticles may also partially contribute to their penetration and accumulation in the leaky vasculature of tumors (44) . In conclusion, using nanomaterials to overcome the drug resistance of malignant tumors could lead to new therapies for cancer patients. This provides a promising chemotherapeutic method to treat tumors at lower, nontoxic dose levels.
Materials and Methods
[Gd@C 82 (OH) 22 ] n Nanoparticles. Gd@C82 was synthesized by the method of Krätschmer-Huffman (45) and extracted under high temperature and high pressure (46) . A high performance liquid chromatography (LC908-C60, Japan Analytical Industry Co.) coupled with 5PBB and Buckyprep columns (Nacalai) was used to separate Gd@C82 from other metallofullerenes (47) . The final purity of the Gd@C82 was greater than 99.5% as measured by MADLI-TOF-MS (Auto-Flex, Bruker). Hydroxylation was performed by alkaline reaction (47, 48) . The Gd@C82(OH) x was isolated using Sephadex G-25 column chromatography (5 × 50 cm 2 ) with an eluent of neutralized water (47) . A fraction of the eluate was collected over a short time interval to ensure that the hydroxyl number distribution was in a narrow range.
MRI. Athymic nude mice were anesthetized using 2% isoflurane, and the tumors were positioned at the center of the RF coil. The physiologic conditions of the animals were monitored using a respiratory monitoring device during the scanning. The animals were scanned using a Bruker 400 MHz, 89-mm NMR spectrometer. After a pilot scan for determining the region of interest, a multislice spin-echo sequence was used with repetition time (TR) of 2 s, echo time (TE) of 25 ms, and slice thickness of 1 mm. The tumor sizes were calculated using Image J software (National Institutes of Health).
Optical imaging. Luciferase was used as a marker in optical images to evaluate the growth of tumors by using the Xenogen IVIS Imaging System (Caliper Life Sciences). Anesthetized mice were i.p. injected with 75 mg/kg D-Luciferin (Caliper Life Sciences) in PBS. Eight minutes after injection, bioluminescence images were acquired using optical imaging. The acquisition time was 0.1 s. Images were set at the indicated pseudocolor scale to show relative bioluminescent changes over time.
Endocytosis of Texas Red-Transferrin. The CP-s and CP-r PC-3-luc cells were labeled with 10 μg/mL Texas Red-transferrin for 20 min at 37°C. Texas Redtransferrin was removed by a PBS rinse. Cells labeled with Texas Red-transferrin were cultured in RPMI medium with 1 μg/mL cisplatin for 40 min, fixed by 70% ethanol in PBS, then imaged by spinning disk confocal microscope (Yokogawa).
[Gd@C 82 (OH) 22 ] n nanoparticles (20 μM) and cisplatin (1 μg/mL) were used in each individual experiment to measure the endocytosis of Texas Red-transferrin.
DNA Adducts Measured by Inductively Coupled Plasma Mass Spectroscopy. The CP-s and CP-r PC-3-luc cells were grown at a density of 10 5 cells/mL. Cells were exposed to 1 μg/mL cisplatin for 40 min with or without 20 μM [Gd@C 82 (OH) 22 ] n nanoparticles. Cells were trypsinized, washed with PBS, and centrifuged for 6 min at 1,000 × g. The DNA was then extracted and digested as reported in the previous studies (49, 50) . The mass spectrometer used was a Thermo Biosystems ×7 inductively coupled plasma mass spectroscopy (ICP-MS) instrument. Measurements were made in the negative ion mode with the source temperature.
Experimental Details. Experimental details on preparation of [Gd@C 82 (OH) 22 ] n nanoparticles, establishment of the cisplatin-resistant cells, transferrin-mediated endocytosis, and cell proliferation assay are included in SI Text.
